OPEN END TURBO CALL WARRANT - MODERNA | Market Closed - Boerse Frankfurt Warrants 13:33:14 2024-06-21 EDT | ||
| 5.52 EUR | +0.36% |
|
| Current month | -11.25% | ||
| 1 month | -10.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 5.52 | +0.36% |
| 24-06-20 | 5.5 | +3.77% |
| 24-06-19 | 5.3 | -4.50% |
| 24-06-18 | 5.55 | -6.88% |
| 24-06-17 | 5.96 | -0.17% |
Real-time Boerse Frankfurt Warrants
Last update June 21, 2024 at 01:33 pm
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| WKN | UL92F9 |
| ISIN | DE000UL92F96 |
| Date issued | 2023-11-16 |
| Strike | 75.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.68 € |
|---|---|
| Lowest since issue | 0.138 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.4
USD
Average target price
145.9
USD
Spread / Average Target
+9.34%
- Stock Market
- Certificates
- Certificat
